Want to see SE:VIMIAN full AI Analyst Report?
Top Page
Vimian Group AB
(VIMIAN)
Select Model
Select Model
Rating:66Neutral
Price Target:
kr36.00
▲(33.83% Upside)
Action:Reiterated
Date:07/20/26
The score is driven primarily by improved profitability and a healthier, less-levered balance sheet, partially offset by volatile cash flow. Technically, the trend is positive but appears overbought. Valuation is the largest headwind due to a high P/E.
Positive Factors
Margin Expansion / Profitability
Operating and net margins have expanded materially (EBIT margin ~13.1% in 2023/24 to ~16.7% TTM; net margin ~3.0% to ~8.5% TTM). Sustainable margin gains indicate improved cost structure and pricing power in veterinary products, supporting durable earnings even if top-line growth moderates.
Negative Factors
Cash Flow Volatility
Cash generation is inconsistent: operating cash flow was negative in 2023 and free cash flow growth fell -18.9% TTM, with FCF roughly 0.87x of net income. This volatility signals sensitivity to working capital and investment timing, constraining capital allocation and increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Margin Expansion / Profitability
Operating and net margins have expanded materially (EBIT margin ~13.1% in 2023/24 to ~16.7% TTM; net margin ~3.0% to ~8.5% TTM). Sustainable margin gains indicate improved cost structure and pricing power in veterinary products, supporting durable earnings even if top-line growth moderates.
Read all positive factors
Vimian Group AB (VIMIAN) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr17.92B
Dividend YieldN/A
Average Volume (3M)772.80K
Price to Earnings (P/E)44.8
Beta (1Y)0.65
Revenue Growth7.86%
EPS Growth55.47%
CountrySE
Employees1,300
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.07
Shares Outstanding527,058,530
10 Day Avg. Volume366,844
30 Day Avg. Volume772,803
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)2.10
Price to Sales (P/S)3.45
P/FCF Ratio16.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr33.00Price Target Upside22.68% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr474.29M
Vimian Group AB Business Overview & Revenue Model
Company Description
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive port...
How the Company Makes Money
Vimian makes money primarily by selling veterinary health products and services through its operating subsidiaries to veterinary clinics, hospitals, laboratories, and other animal health customers. Key revenue streams include: (1) Product sales: r...
Vimian Group AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 449.28M | 425.00M | 374.80M | 331.73M | 281.31M | 173.35M |
| Gross Profit | 250.19M | 292.80M | 258.30M | 229.43M | 193.99M | 122.85M |
| EBITDA | 121.55M | 104.70M | 82.80M | 69.19M | 39.20M | 36.16M |
| Net Income | 36.79M | 31.30M | 18.50M | 9.84M | -7.20M | 6.59M |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.11B | 1.11B | 973.68M | 923.56M | 640.72M |
| Cash, Cash Equivalents and Short-Term Investments | 51.74M | 55.00M | 64.80M | 37.50M | 42.19M | 55.11M |
| Total Debt | 279.56M | 238.70M | 233.60M | 313.80M | 220.96M | 180.37M |
| Total Liabilities | 440.79M | 401.00M | 403.30M | 446.97M | 442.06M | 282.08M |
| Stockholders Equity | 736.99M | 698.90M | 699.90M | 526.37M | 481.81M | 357.41M |
Cash Flow | ||||||
| Free Cash Flow | 78.74M | 90.60M | 43.90M | -43.48M | 15.01M | 4.52M |
| Operating Cash Flow | 93.02M | 105.70M | 58.10M | -28.58M | 25.31M | 16.01M |
| Investing Cash Flow | -78.67M | -112.80M | -76.00M | -77.68M | -188.53M | -115.00M |
| Financing Cash Flow | -32.88M | -1.20M | 44.80M | 100.55M | 150.23M | 123.94M |
Vimian Group AB Technical Analysis
Positive
26.90
Price Trends
30.56
Positive
29.61
Positive
29.30
Positive
Market Momentum
1.13
Negative
67.75
Neutral
80.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Positive. The current price of 26.9 is below the 20-day moving average (MA) of 32.64, below the 50-day MA of 30.56, and below the 200-day MA of 29.30, indicating a bullish trend. The MACD of 1.13 indicates Negative momentum. The RSI at 67.75 is Neutral, neither overbought nor oversold. The STOCH value of 80.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VIMIAN.
Vimian Group AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | kr8.27B | 34.20 | 16.15% | ― | 18.53% | 20.60% | |
72 Outperform | kr19.71B | 33.05 | 10.82% | 0.95% | 0.82% | 77.45% | |
67 Neutral | kr13.15B | 18.35 | 12.72% | 3.55% | -2.14% | -2.98% | |
66 Neutral | kr17.92B | 44.79 | 5.17% | ― | 7.86% | 55.47% | |
53 Neutral | kr18.49B | -35.74 | -6.37% | 5.11% | -7.22% | -319.36% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr11.66B | -2.34 | -53.29% | 0.80% | -4.21% | -1194.93% |
* Healthcare Sector Average
SE:VIMIAN
Vimian Group AB
34.00
1.36
4.17%
SE:EKTA.B
Elekta AB
48.38
3.84
8.61%
SE:VITR
Vitrolife AB
86.10
-50.10
-36.78%
SE:ALIF.B
AddLife AB
161.60
-6.16
-3.67%
SE:NOLA.B
Nolato AB
48.80
-6.18
-11.23%
SE:MCAP
MedCap AB
548.50
-108.50
-16.51%
Vimian Group AB Corporate Events
Vimian issues and repurchases shares for 2026 long-term incentive plan
Jul 17, 2026
Vimian Group AB, a Stockholm-based global animal health company, focuses on Specialty Pharma, MedTech, Veterinary Services and Diagnostics for companion animals. With operations in more than 80 markets and annual revenues of approximately EUR 425 ...
Vimian Delivers Double-Digit Growth and Strong Margins in Q2 2026
Jul 17, 2026
Vimian Group AB reported a strong second quarter in 2026, with revenue rising 17 per cent to EUR 121.6 million and organic growth of 12 per cent, supplemented by contributions from acquisitions despite a minor negative currency effect. Profitabili...
Vimian schedules Q2 2026 interim report and investor audiocast
Jul 7, 2026
Vimian Group AB will publish its interim report for the second quarter of 2026 on 17 July at 07:45 CET, followed by an audiocast for investors, analysts and media at 09:00 CET. Chief executive Alireza Tajbakhsh and chief financial officer Carl-Joh...
Vimian Updates Share and Vote Count After Warrant Exercises
Jun 30, 2026
Vimian Group AB reported an increase in its share capital during June following the exercise of warrants issued under a program approved at the 2023 Annual General Meeting. The company added 1,093,738 ordinary shares, resulting in the same number ...
Vimian launches subscription phase of 2023–2026 employee warrant program
Jun 18, 2026
Vimian Group AB has opened the subscription period for its 2023–2026 long-term incentive warrant program, allowing employees to subscribe for ordinary shares at a set exercise price until mid-July 2026. Each warrant entitles the holder to ac...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.